Top

Current Cardiovascular Imaging Reports

Published in:

Open Access 01-03-2018 | Molecular Imaging (J Wu and P Nguyen, Section Editors)

PET Imaging of Cardiac Hypoxia: Hitting Hypoxia Where It Hurts

Authors: Victoria R. Pell, Friedrich Baark, Filipa Mota, James E. Clark, Richard Southworth

Published in: Current Cardiovascular Imaging Reports | Issue 3/2018

Abstract

Purpose of Review

In this review, we outline the potential for hypoxia imaging as a diagnostic and prognostic tool in cardiology. We describe the lead hypoxia PET radiotracers currently in development and propose a rationale for how they should most appropriately be screened and validated.

Recent Findings

While the majority of hypoxia imaging agents has been developed for oncology, the requirements for hypoxia imaging in cardiology are different. Recent work suggests that the bis(thiosemicarbazone) family of compounds may be capable of detecting the subtle degrees of hypoxia associated with cardiovascular syndromes, and that they have the potential to be “tuned” to provide different tracers for different applications.

Summary

New tracers currently in development show significant promise for imaging evolving cardiovascular disease. Fundamental to their exploitation is their careful, considered validation and characterization so that the information they provide delivers the greatest prognostic insight achievable.

De Boer RA, Pinto YM, Van Veldhuisen DJ. The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities. Microcirculation. 2003;10(2):113–26. https://doi.org/10.1080/713773607.CrossRefPubMed

Lanza GA, Crea F. Primary coronary microvascular dysfunction: clinical presentation, pathophysiology, and management. Circulation. 2010;121(21):2317–25. https://doi.org/10.1161/CIRCULATIONAHA.109.900191.CrossRefPubMed

Giordano FJ. Oxygen oxidative stress, hypoxia, and heart failure. J Clin Invest. 2005;115(3):500–8.CrossRefPubMedPubMedCentral

Semenza GL. Hypoxia-inducible factor 1 and cardiovascular disease. Annu Rev Physiol. 2014;76(1):39–56. https://doi.org/10.1146/annurev-physiol-021113-170322.CrossRefPubMed

Hilfiker-Kleiner D, Landmesser U, Drexler H. Molecular mechanisms in heart failure: focus on cardiac hypertrophy, inflammation, angiogenesis, and apoptosis. J Am Coll Cardiol. 2006;48(9, Supplement):A56–66.CrossRef

Leung DY, Leung M. Non-invasive/invasive imaging: significance and assessment of coronary microvascular dysfunction. Heart. 2011;97(7):587–95.CrossRefPubMed

Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med. 2007;356(8):830–40. https://doi.org/10.1056/NEJMra061889.CrossRefPubMed

Cohn JN, Quyyumi AA, Hollenberg NK, Jamerson KA. Surrogate markers for cardiovascular disease: functional markers. Circulation. 2004;109(25 Suppl 1):IV31–46. https://doi.org/10.1161/01.CIR.0000133442.99186.39.PubMed

Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000;101(16):1899–906. https://doi.org/10.1161/01.CIR.101.16.1899.CrossRefPubMed

10.

Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251–9. https://doi.org/10.1056/NEJMoa052256.CrossRefPubMed

11.

Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11(9):507–15. https://doi.org/10.1038/nrcardio.2014.83.CrossRefPubMed

12.

Oktay AA, Shah SJ. Diagnosis and management of heart failure with preserved ejection fraction: 10 key lessons. Curr Cardiol Rev. 2015;11(1):42–52.CrossRefPubMed

13.

Giamouzis G, Schelbert EB, Butler J. Growing evidence linking microvascular dysfunction with heart failure with preserved ejection fraction. J Am Heart Assoc. 2016;5(2):e003259. https://doi.org/10.1161/JAHA.116.003259.CrossRefPubMedPubMedCentral

14.

Kato S, Saito N, Kirigaya H, Gyotoku D, Iinuma N, Kusakawa Y, et al. Impairment of coronary flow reserve evaluated by phase contrast cine-magnetic resonance imaging in patients with heart failure with preserved ejection fraction. J Am Heart Assoc. 2016;5(2):e002649. https://doi.org/10.1161/JAHA.115.002649.CrossRefPubMedPubMedCentral

15.

Sinusas AJ. The potential for myocardial imaging with hypoxia markers. Semin Nucl Med. 1999;29(4):330–8. https://doi.org/10.1016/S0001-2998(99)80020-8.CrossRefPubMed

16.

Li D, Dhawale P, Rubin PJ, Haacke EM, Gropler RJ. Myocardial signal response to dipyridamole and dobutamine: demonstration of the BOLD effect using a double-echo gradient-echo sequence. Magn Reson Med. 1996;36(1):16–20. https://doi.org/10.1002/mrm.1910360105.CrossRefPubMed

17.

Huang TY, Liu YJ, Stemmer A, Poncelet BP. T2 measurement of the human myocardium using a T2-prepared transient-state TrueFISP sequence. Magn Reson Med. 2007;57(5):960–6. https://doi.org/10.1002/mrm.21208.CrossRefPubMed

18.

Seddon BM, Honess DJ, Vojnovic B, Tozer GM, Workman P. Measurement of tumor oxygenation: in vivo comparison of a luminescence fiber-optic sensor and a polarographic electrode in the p22 tumor. Radiat Res. 2001;155(6):837–46. https://doi.org/10.1667/0033-7587(2001)155[0837:MOTOIV]2.0.CO;2.

19.

Tran LB, Bol A, Labar D, Jordan B, Magat J, Mignion L, et al. Hypoxia imaging with the nitroimidazole 18F-FAZA PET tracer: a comparison with OxyLite, EPR oximetry and 19F-MRI relaxometry. Radiother Oncol. 2012;105(1):29–35. https://doi.org/10.1016/j.radonc.2012.04.011.CrossRefPubMed

20.

Machac J. Cardiac positron emission tomography imaging. Semin Nucl Med. 2005;35(1):17–36. https://doi.org/10.1053/j.semnuclmed.2004.09.002.CrossRefPubMed

21.

Kudo T. Metabolic imaging using PET. Eur J Nucl Med Mol Imaging. 2007;34(Suppl 1):S49–61.CrossRefPubMed

22.

Coort SL, Bonen A, van der Vusse GJ, Glatz JF, Luiken JJ. Cardiac substrate uptake and metabolism in obesity and type-2 diabetes: role of sarcolemmal substrate transporters. Mol Cell Biochem. 2007;299(1–2):5–18. https://doi.org/10.1007/s11010-005-9030-5.CrossRefPubMed

23.

Southworth R. Hexokinase-mitochondrial interaction in cardiac tissue: implications for cardiac glucose uptake, the 18FDG lumped constant and cardiac protection. J Bioenerg Biomembr. 2009;41(2):187–93. https://doi.org/10.1007/s10863-009-9207-9.CrossRefPubMed

24.

• Feher A, Sinusas AJ. Quantitative assessment of coronary microvascular function: dynamic single-photon emission computed tomography, positron emission tomography, ultrasound, computed tomography, and magnetic resonance imaging. Circ Cardiovasc Imaging. 2017;10(8):e006427. https://doi.org/10.1161/CIRCIMAGING.117.006427. Key review of state-of-the-art in imaging coronary microvascular disease. CrossRefPubMed

25.

Handley MG, Medina RA, Nagel E, Blower PJ, Southworth R. PET imaging of cardiac hypoxia: opportunities and challenges. J Mol Cell Cardiol. 2011;51(5):640–50. https://doi.org/10.1016/j.yjmcc.2011.07.005.CrossRefPubMedPubMedCentral

26.

Valencia A, Burgess JH. Arterial hypoxemia following acute myocardial infarction. Circulation. 1969;40(5):641–52. https://doi.org/10.1161/01.CIR.40.5.641.CrossRefPubMed

27.

Des Tombe AL, Van Beek-Harmsen BJ, Lee-De Groot MB, Van Der Laarse WJ. Calibrated histochemistry applied to oxygen supply and demand in hypertrophied rat myocardium. Microsc Res Tech. 2002;58(5):412–20. https://doi.org/10.1002/jemt.10153.CrossRefPubMed

28.

Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med. 2008;49(Suppl 2):129s–48s.CrossRefPubMed

29.

Strauss HW, Nunn A, Linder K. Nitroimidazoles for imaging hypoxic myocardium. J Nucl Cardiol. 1995;2(5):437–45. https://doi.org/10.1016/S1071-3581(05)80031-5.CrossRefPubMed

30.

Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med. 1995;22(3):265–80. https://doi.org/10.1007/BF01081524.CrossRefPubMed

31.

Dearling JL, Lewis JS, Mullen GE, Welch MJ, Blower PJ. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. J Biol Inorg Chem: JBIC. 2002;7(3):249–59. https://doi.org/10.1007/s007750100291.CrossRefPubMed

32.

Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38(7):1155–60.PubMed

33.

Chia K, Fleming IN, Blower PJ. Hypoxia imaging with PET: which tracers and why? Nucl Med Commun. 2012;33(3):217–22. https://doi.org/10.1097/MNM.0b013e32834eacb7.CrossRefPubMed

34.

Sutherland FJ, Hearse DJ. The isolated blood and perfusion fluid perfused heart. Pharmacol Res. 2000;41(6):613–27. https://doi.org/10.1006/phrs.1999.0653.CrossRefPubMed

35.

Yabe T, Mitsunami K, Inubushi T, Kinoshita M. Quantitative measurements of cardiac phosphorus metabolites in coronary artery disease by 31P magnetic resonance spectroscopy. Circulation. 1995;92(1):15–23. https://doi.org/10.1161/01.CIR.92.1.15.CrossRefPubMed

36.

Buchthal SD, den Hollander JA, Merz CN, Rogers WJ, Pepine CJ, Reichek N, et al. Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms. N Engl J Med. 2000;342(12):829–35. https://doi.org/10.1056/NEJM200003233421201.CrossRefPubMed

37.

Smith CS, Bottomley PA, Schulman SP, Gerstenblith G, Weiss RG. Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium. Circulation. 2006;114(11):1151–8. https://doi.org/10.1161/CIRCULATIONAHA.106.613646.CrossRefPubMedPubMedCentral

38.

Rankin EB, Giaccia AJ. Hypoxic control of metastasis. Science. 2016;352(6282):175–80.CrossRefPubMedPubMedCentral

39.

Barker HE, Paget JT, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015;15(7):409–25. https://doi.org/10.1038/nrc3958.CrossRefPubMedPubMedCentral

40.

Ballinger JR. Imaging hypoxia in tumors. Semin Nucl Med. 2001;31(4):321–9. https://doi.org/10.1053/snuc.2001.26191.CrossRefPubMed

41.

Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK, Graham MM, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys. 1996;36(2):417–28. https://doi.org/10.1016/S0360-3016(96)00325-2.CrossRefPubMed

42.

Martin GV, Cerqueira MD, Caldwell JH, Rasey JS, Embree L, Krohn KA. Fluoromisonidazole. A metabolic marker of myocyte hypoxia. Circ Res. 1990;67(1):240–4. https://doi.org/10.1161/01.RES.67.1.240.CrossRefPubMed

43.

Shelton ME, Dence CS, Hwang DR, Welch MJ, Bergmann SR. Myocardial kinetics of fluorine-18 misonidazole: a marker of hypoxic myocardium. J Nucl Med. 1989;30(3):351–8.PubMed

44.

Shelton ME, Dence CS, Hwang DR, Herrero P, Welch MJ, Bergmann SR. In vivo delineation of myocardial hypoxia during coronary occlusion using fluorine-18 fluoromisonidazole and positron emission tomography: a potential approach for identification of jeopardized myocardium. J Am Coll Cardiol. 1990;16(2):477–85. https://doi.org/10.1016/0735-1097(90)90606-P.CrossRefPubMed

45.

Mateo J, Izquierdo-Garcia D, Badimon JJ, Fayad ZA, Fuster V. Noninvasive assessment of hypoxia in rabbit advanced atherosclerosis using (1)(8)F-fluoromisonidazole positron emission tomographic imaging. Circ Cardiovasc Imaging. 2014;7(2):312–20. https://doi.org/10.1161/CIRCIMAGING.113.001084.CrossRefPubMedPubMedCentral

46.

Manabe O, Hirata K, Shozo O, Shiga T, Uchiyama Y, Kobayashi K, et al. 18F-fluoromisonidazole (FMISO) PET may have the potential to detect cardiac sarcoidosis. J Nucl Cardiol. 2017;24(1):329–31. https://doi.org/10.1007/s12350-016-0495-2.CrossRefPubMed

47.

Joshi FR, Manavaki R, Fryer TD, Figg NL, Sluimer JC, Aigbirhio FI, et al. Vascular imaging with 18F-fluorodeoxyglucose positron emission tomography is influenced by hypoxia. J Am Coll Cardiol. 2017;69(14):1873–4. https://doi.org/10.1016/j.jacc.2017.01.050.CrossRefPubMedPubMedCentral

48.

•• van der Valk FM, Sluimer JC, Voo SA, Verberne HJ, Nederveen AJ, Windhorst AD, et al. In vivo imaging of hypoxia in atherosclerotic plaques in humans. JACC Cardiovasc Imaging. 2015;8(11):1340–1. Demonstration of clinical proof-of-concept of hypoxia-specific PET imaging to identify evolving atherosclerotic plaque. CrossRefPubMed

49.

Silvola JM, Saraste A, Forsback S, Laine VJ, Saukko P, Heinonen SE, et al. Detection of hypoxia by [18F]EF5 in atherosclerotic plaques in mice. Arterioscler Thromb Vasc Biol. 2011;31(5):1011–5. https://doi.org/10.1161/ATVBAHA.110.221440.CrossRefPubMed

50.

• Medina RA, Mariotti E, Pavlovic D, Shaw KP, Eykyn TR, Blower PJ, et al. 64Cu-CTS: a promising radiopharmaceutical for the identification of low-grade cardiac hypoxia by PET. J Nucl Med. 2015;56(6):921–6. https://doi.org/10.2967/jnumed.114.148353.First description of a PET hypoxia imaging agent better suited to cardiovascular applications than 64CuATSM. CrossRefPubMed

51.

Handley MG, Medina RA, Mariotti E, Kenny GD, Shaw KP, Yan R, et al. Cardiac hypoxia imaging: second-generation analogues of 64Cu-ATSM. J Nucl Med. 2014;55(3):488–94. https://doi.org/10.2967/jnumed.113.129015.CrossRefPubMed

52.

Handley MG, Medina RA, Paul RL, Blower PJ, Southworth R. Demonstration of the retention of 64Cu-ATSM in cardiac myocytes using a novel incubation chamber for screening hypoxia-dependent radiotracers. Nucl Med Commun. 2013;34(10):1015–22. https://doi.org/10.1097/MNM.0b013e328363f25e.CrossRefPubMed

53.

Fujibayashi Y, Cutler CS, Anderson CJ, McCarthy DW, Jones LA, Sharp T, et al. Comparative studies of Cu-64-ATSM and C-11-acetate in an acute myocardial infarction model: ex vivo imaging of hypoxia in rats. Nucl Med Biol. 1999;26(1):117–21. https://doi.org/10.1016/S0969-8051(98)00049-3.CrossRefPubMed

54.

Shaughnessy F, Mariotti E, Shaw KP, Eykyn TR, Blower PJ, Siow R, et al. Modification of intracellular glutathione status does not change the cardiac trapping of (64)Cu(ATSM). EJNMMI Res. 2014;4(1):40. https://doi.org/10.1186/s13550-014-0040-8.CrossRefPubMedPubMedCentral

55.

Wada K, Fujibayashi Y, Tajima N, Yokoyama A. Cu-ATSM, an intracellular-accessible superoxide dismutase (SOD)-like copper complex: evaluation in an ischemia-reperfusion injury model. Biol Pharm Bull. 1994;17(5):701–4. https://doi.org/10.1248/bpb.17.701.CrossRefPubMed

56.

Takahashi N, Fujibayashi Y, Yonekura Y, Welch MJ, Waki A, Tsuchida T, et al. Copper-62 ATSM as a hypoxic tissue tracer in myocardial ischemia. Ann Nucl Med. 2001;15(3):293–6. https://doi.org/10.1007/BF02987849.CrossRefPubMed

57.

•• Nie X, Randolph GJ, Elvington A, Bandara N, Zheleznyak A, Gropler RJ, et al. Imaging of hypoxia in mouse atherosclerotic plaques with (64)Cu-ATSM. Nucl Med Biol. 2016;43(9):534–42. https://doi.org/10.1016/j.nucmedbio.2016.05.011. Demonstration of hypoxia-targeting capacity of 64CuATSM in atherosclerotic plaque identification and staging. CrossRefPubMedPubMedCentral

58.

Nie X, Laforest R, Elvington A, Randolph GJ, Zheng J, Voller T, et al. PET/MRI of hypoxic atherosclerosis using 64Cu-ATSM in a rabbit model. J Nucl Med. 2016;57(12):2006–11. https://doi.org/10.2967/jnumed.116.172544.CrossRefPubMedPubMedCentral

59.

Lee ST, Scott AM. Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole. Semin Nucl Med. 2007;37(6):451–61. https://doi.org/10.1053/j.semnuclmed.2007.07.001.CrossRefPubMed

60.

Peeters SG, Zegers CM, Lieuwes NG, van Elmpt W, Eriksson J, van Dongen GA, et al. A comparative study of the hypoxia PET tracers [(1)(8)F]HX4, [(1)(8)F]FAZA, and [(1)(8)F]FMISO in a preclinical tumor model. Int J Radiat Oncol Biol Phys. 2015;91(2):351–9. https://doi.org/10.1016/j.ijrobp.2014.09.045.CrossRefPubMed

61.

Fujibayashi Y, Matsumoto K, Yonekura Y, Konishi J, Yokoyama A. A new zinc-62/copper-62 generator as a copper-62 source for PET radiopharmaceuticals. J Nucl Med. 1989;30(11):1838–42.PubMed

62.

Dearling JL, Packard AB. Some thoughts on the mechanism of cellular trapping of Cu(II)-ATSM. Nucl Med Biol. 2010;37(3):237–43. https://doi.org/10.1016/j.nucmedbio.2009.11.004.CrossRefPubMed

63.

Maurer RI, Blower PJ, Dilworth JR, Reynolds CA, Zheng Y, Mullen GE. Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals. J Med Chem. 2002;45(7):1420–31. https://doi.org/10.1021/jm0104217.CrossRefPubMed

64.

Paterson BM, Donnelly PS. Copper complexes of bis(thiosemicarbazones): from chemotherapeutics to diagnostic and therapeutic radiopharmaceuticals. Chem Soc Rev. 2011;40(5):3005–18. https://doi.org/10.1039/c0cs00215a.CrossRefPubMed

65.

Yip C, Blower PJ, Goh V, Landau DB, Cook GJ. Molecular imaging of hypoxia in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2015;42(6):956–76. https://doi.org/10.1007/s00259-015-3009-6.CrossRefPubMed

66.

McQuade P, Martin KE, Castle TC, Went MJ, Blower PJ, Welch MJ, et al. Investigation into 64Cu-labeled Bis(selenosemicarbazone) and Bis(thiosemicarbazone) complexes as hypoxia imaging agents. Nucl Med Biol. 2005;32(2):147–56. https://doi.org/10.1016/j.nucmedbio.2004.10.004.CrossRefPubMed

67.

Dearling JL, Lewis JS, Mullen GE, Rae MT, Zweit J, Blower PJ. Design of hypoxia-targeting radiopharmaceuticals: selective uptake of copper-64 complexes in hypoxic cells in vitro. Eur J Nucl Med. 1998;25(7):788–92. https://doi.org/10.1007/s002590050283.CrossRefPubMed

68.

Brown OC, Baguna Torres J, Holt KB, Blower PJ, Went MJ. Copper complexes with dissymmetrically substituted bis(thiosemicarbazone) ligands as a basis for PET radiopharmaceuticals: control of redox potential and lipophilicity. Dalton Trans. 2017;46(42):14612–30. https://doi.org/10.1039/C7DT02008B.CrossRefPubMed

69.

Tarkin JM, Joshi FR, Rudd JH. PET imaging of inflammation in atherosclerosis. Nat Rev Cardiol. 2014;11(8):443–57. https://doi.org/10.1038/nrcardio.2014.80.CrossRefPubMed

70.

Moss AJ, Adamson PD, Newby DE, Dweck MR. Positron emission tomography imaging of coronary atherosclerosis. Futur Cardiol. 2016;12(4):483–96. https://doi.org/10.2217/fca-2016-0017.CrossRef

71.

Joseph P, Tawakol A. Imaging atherosclerosis with positron emission tomography. Eur Heart J. 2016;37(39):2974–80. https://doi.org/10.1093/eurheartj/ehw147.CrossRefPubMed

72.

Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340(2):115–26.CrossRefPubMed

73.

Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–43. https://doi.org/10.1161/hc0902.104353.CrossRefPubMed

74.

Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002;105(23):2708–11. https://doi.org/10.1161/01.CIR.0000020548.60110.76.CrossRefPubMed

75.

Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006;48(9):1818–24. https://doi.org/10.1016/j.jacc.2006.05.076.CrossRefPubMed

76.

Rudd JH, Narula J, Strauss HW, Virmani R, Machac J, Klimas M, et al. Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? J Am Coll Cardiol. 2010;55(23):2527–35. https://doi.org/10.1016/j.jacc.2009.12.061.CrossRefPubMed

77.

Williams G, Kolodny GM. Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. AJR Am J Roentgenol. 2008;190(2):W151–6. https://doi.org/10.2214/AJR.07.2409.CrossRefPubMed

78.

de Groot M, Meeuwis AP, Kok PJ, Corstens FH, Oyen WJ. Influence of blood glucose level, age and fasting period on non-pathological FDG uptake in heart and gut. Eur J Nucl Med Mol Imaging. 2005;32(1):98–101. https://doi.org/10.1007/s00259-004-1670-2.CrossRefPubMed

79.

Rogers IS, Nasir K, Figueroa AL, Cury RC, Hoffmann U, Vermylen DA, et al. Feasibility of FDG imaging of the coronary arteries: comparison between acute coronary syndrome and stable angina. JACC Cardiovasc Imaging. 2010;3(4):388–97. https://doi.org/10.1016/j.jcmg.2010.01.004.CrossRefPubMed

80.

Heughan C, Niinikoski J, Hunt TK. Oxygen tensions in lesions of experimental atherosclerosis of rabbits. Atherosclerosis. 1973;17(3):361–7. https://doi.org/10.1016/0021-9150(73)90027-0.CrossRefPubMed

81.

Bjornheden T, Levin M, Evaldsson M, Wiklund O. Evidence of hypoxic areas within the arterial wall in vivo. Arterioscler Thromb Vasc Biol. 1999;19(4):870–6. https://doi.org/10.1161/01.ATV.19.4.870.CrossRefPubMed

82.

Sluimer JC, Gasc JM, van Wanroij JL, Kisters N, Groeneweg M, Sollewijn Gelpke MD, et al. Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J Am Coll Cardiol. 2008;51(13):1258–65. https://doi.org/10.1016/j.jacc.2007.12.025.CrossRefPubMed

83.

Folco EJ, Sheikine Y, Rocha VZ, Christen T, Shvartz E, Sukhova GK, et al. Hypoxia but not inflammation augments glucose uptake in human macrophages: implications for imaging atherosclerosis with 18fluorine-labeled 2-deoxy-D-glucose positron emission tomography. J Am Coll Cardiol. 2011;58(6):603–14. https://doi.org/10.1016/j.jacc.2011.03.044.CrossRefPubMed

Title: PET Imaging of Cardiac Hypoxia: Hitting Hypoxia Where It Hurts
Authors: Victoria R. Pell
Friedrich Baark
Filipa Mota
James E. Clark
Richard Southworth
Publication date: 01-03-2018
Publisher: Springer US
Published in: Current Cardiovascular Imaging Reports / Issue 3/2018
Print ISSN: 1941-9066
Electronic ISSN: 1941-9074
DOI: https://doi.org/10.1007/s12410-018-9447-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

PET Imaging of Cardiac Hypoxia: Hitting Hypoxia Where It Hurts

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page